Results 91 to 100 of about 6,803 (197)

Sugammadex-Enhanced Neuronal Apoptosis following Neonatal Sevoflurane Exposure in Mice

open access: yesAnesthesiology Research and Practice, 2016
In rodents, neonatal sevoflurane exposure induces neonatal apoptosis in the brain and results in learning deficits. Sugammadex is a new selective neuromuscular blockade (NMB) binding agent that anesthesiologists can use to achieve immediate reversal of ...
Maiko Satomoto   +3 more
doaj   +1 more source

Reversión del Bloqueo Neuromuscular Profundo Inducido por Altas Dosis de Rocuronio mediante Sugammadex en Dos Momentos Diferentes

open access: yesRevista Electrónica de AnestesiaR, 2009
El Sugammadex es una gamma-ciclodextrina modificada, diseñada específicamente para unirse selectivamente a los Relajantes NeuroMusculares (RNM) esteroideos, con especial afinidad para el Rocuronio.
Antonio Planas Roca
doaj   +1 more source

Impact of Neostigmine and Sugammadex on Time to Leaving the Operating Room in a Community Hospital

open access: yesINNOVATIONS in Pharmacy, 2020
Purpose: The purpose of this study was to evaluate the impact of sugammadex on operating room (OR) times versus neostigmine in patients recovering from rocuronium or vecuronium induced neuromuscular blockade.
Julie John   +7 more
doaj   +1 more source

Sugammadex Use in Adult Surgery Patients at Kingston Health Sciences Centre: A Drug Use Evaluation [PDF]

open access: yes, 2021
Pharmacy residents have the opportunity to complete a research project during their residency training, which provides them with skills on how to conduct and manage a research project.
Egan, Leah
core  

Prediction of Optimal Reversal Dose of Sugammadex after Rocuronium Administration in Adult Surgical Patients

open access: yesAnesthesiology Research and Practice, 2014
The objective of this study was to determine the point after sugammadex administration at which sufficient or insufficient dose could be determined, using first twitch height of train-of-four (T1 height) or train-of-four ratio (TOFR) as indicators ...
Shigeaki Otomo   +6 more
doaj   +1 more source

Data from: Low-dose sugammadex reverses moderate rocuronium-induced neuromuscular block in horses

open access: yes
Please cite as: Manuel Martin-Flores, Daniel Sakai, Joaquin Araos, Luis Campoy. (2024) Data from: Low-dose sugammadex reverses moderate rocuronium-induced neuromuscular block in horses. [dataset] Cornell University eCommons Repository.
Araos, Joaquin   +3 more
core   +1 more source

Sugammadex to reverse neuromuscular blockade in a child with a past history of cardiac transplantation

open access: yesAnnals of Cardiac Anaesthesia, 2017
Sugammadex is a novel agent for the reversal of neuromuscular blockade. The speed and efficacy of reversal with sugammadex are significantly faster than acetylcholinesterase inhibitors, such as neostigmine.
Karen Miller   +2 more
doaj   +1 more source

Effects of sugammadex and rocuronium on electro-mechanical activity of cardiac myocytes [PDF]

open access: yesKorean Journal of Anesthesiology
Background Sugammadex reverses the effects of steroidal neuromuscular-blocking agents, such as rocuronium, by encapsulating these agents. Its cardiovascular adverse effects include QTc prolongation, hypotension, bradycardia, atrioventricular block ...
Oguzhan Arun   +6 more
doaj   +1 more source

The use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impact

open access: yes, 2016
Edoardo De Robertis,1 Geremia Zito Marinosci,1 Giovanni Marco Romano,1 Ornella Piazza,2 Michele Iannuzzi,1 Fabrizio Cirillo,1 Stefania De Simone,3 Giuseppe Servillo,1 1Department of Neurosciences, Reproductive and Odontostomatologic Sciences, University ...
De Robertis E   +7 more
core  

Sugammadex for our little ones: a brief narrative review [PDF]

open access: yes
Sugammadex, the first noncompetitive antagonist developed for the reversal of neuromuscular blockade (NMB), is one of the few drugs that has revolutionized anesthetic practice.
Woosuk Chung, Soomin Lee
core   +2 more sources

Home - About - Disclaimer - Privacy